<DOC>
	<DOCNO>NCT00088023</DOCNO>
	<brief_summary>The purpose study determine safety short intravenous infusion PT-523 patient solid tumor fail curative survival prolong therapy therapy exist .</brief_summary>
	<brief_title>Safety Study PT-523 Cancer Patients Treat Solid Tumors Including Preliminary Assessment Effectiveness</brief_title>
	<detailed_description>The primary objective study 1 ) evaluate safety short intravenous infusion PT-523 administer day 1 , 8 , 15 28-day cycle patient solid tumor fail curative survival prolong therapy therapy exist ; 2 ) establish maximum tolerate dose ( MTD ) identify dose limit toxicity ( DLT ) PT-523 . The secondary objective study determine pharmacokinetics evaluate preliminary efficacy PT-523 .</detailed_description>
	<criteria>Presence metastatic inoperable malignancy , leukemia primary central nervous system ( CNS ) tumor , know curative survival prolong palliative therapy , failure therapy . Age great equal 18 year . Life expectancy great equal 2 month . ECOG performance status 0 2 . Adequate organ function bone marrow reserve . Use appropriate contraceptive method . Sign patient inform consent . Active brain metastasis . Presence thirdspace fluid collection ( pleural effusion , ascites ) . Major surgery within 3 week prior dose . Prior chemotherapy radiation therapy within 3 week prior dose ( 6 week nitrosoureas mitomycinC ) . Prior antifolate therapy permit , long administer within 3 week prior dose PT523 . Prior bone marrow transplantation . Presence uncontrolled serious medical psychiatric illness . Patients require radiation therapy . There limitation extent type prior therapy receive patient time interval indicate , long patient demonstrate complete recovery adverse effect , fulfills relevant inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Solid tumor</keyword>
</DOC>